glp 1 receptor agonist for weight loss What Are GLP-1 Agonists Loss? Frontiers | GLP−1 receptor agonists

Surv Ophthalmol

November 2023 : Eli Lilly received US FDA approval for ZEPBOUND, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors

D., Satylganova, A., Skovgaard, D., & McGowan, B

Dual and Triple IncretinBased Coagonists: Novel Therapeutics for Obesity and Diabetes

Moreover, given the high cost of these medications and the limited access for uninsured, underinsured, or low-income individualswho may stand to benefit the mostthere is a critical need for policies that enhance access to these therapies to mitigate potential health disparities